47 results about "Her Disease" patented technology

A system and method for endoluminal grafting of a main anatomic conduit in its diseased state in which it dilates to pose a life threatening condition and its various conduits that emanate from the main anatomic conduit. The grafting system comprises an endoaortic graft having at least one opening therein and at least one branch graft that is passable through the opening of the endoaortic graft into the branch anatomic conduit(s) such that the junction between the branch graft and the endoaortic graft is substantially fluid tight. A system and method for delivery of the endoaortic graft and also a system and method for efficient alignment and deployment of the branch (e.g., side branch) graft such that the coupling of the branch graft with the endoaortic graft is efficient and exact and fluid-tight; and a system and method for coupling the branch to the endoaortic graft via a coupling mechanism employing a memory metal alloy; a system and method for the proper and exact alignment of the endoaortic graft and the branch using magnetic force of a suitable nature, and which does not use the magnetic force as the coupling mechanism.

A system and method for endoluminal grafting of a main anatomic conduit in its diseased state in which it dilates to pose a life threatening condition and its various conduits that emanate from the main anatomic conduit. The grafting system comprises an endoaortic graft having at least one opening therein and at least one branch graft that is passable through the opening of the endoaortic graft into the branch anatomic conduit(s) such that the junction between the branch graft and the endoaortic graft is substantially fluid tight. A system and method for delivery of the endoaortic graft and also a system and method for efficient alignment and deployment of the branch (e.g., side branch) graft such that the coupling of the branch graft with the endoaortic graft is efficient and exact and fluid-tight; and a system and method for coupling the branch to the endoaortic graft via a coupling mechanism employing a memory metal alloy; a system and method for the proper and exact alignment of the endoaortic graft and the branch using magnetic force of a suitable nature, and which does not use the magnetic force as the coupling mechanism.

A computerized system allows intercommunication of patients with respect to the treatment of their diseases. This system includes an electronic medical record database providing electronic medical records of a given set of patients as developed by healthcare professionals and linked to an anonymous identifier for each patient and a set of terminal devices accessible to the patients allowing for the electronic exchange of information through a display and data input device. A server system connects the anonymous medical record database and the terminal devices and executes a stored program to: (1) allow an authenticated connection by a given patient to the server system through a terminal device and associate the connection with an anonymous identifier; (2) permit authoring by the given patient of a patient site viewable on a terminal device incorporating medical records from the anonymous medical record database associated with the anonymous identifier; and (3) identify to the given patient other patient sites for other patients having shared medical conditions according to a predetermined clustering of data of the anonymous medical record database.

A molecular classification procedure based on activity levels of modules in protein networks, wherein the proteins are biomarkers for chronic lymphocytic leukemia (CLL), and method for use of the subnetworks to distinguish between patients at low or high risk of progression of their disease.

The invention discloses a method by which the health care professional or patient may draw upon historical medical data concerning patients similarly situated in medical condition, to assist him / her in deciding on a clinical intervention procedure to select. This method is specifically tailored to the patient, as data is provided and evaluated from only similarly situated patients, and provides an expectation of potential outcome of the patient should one or the other of the options be selected. The invention further provides a database that may be used in order to provide this comparison based evaluation method. A computer based software system is further disclosed that implements the method. The invention more speiocifically provides a method by which a post-coronary event patient may make an informed decision of which post-coronary revascularization procedure to undergo in the future management of his disease. This method employs the patient's health status date (symptoms, function and quality of life), and provides projections of the patient's expected survival, risk, and 1-year health status outcome from the selection of revascularization procedure, such as Coronary Artery Bypass Grafting (CABG) or Percutaneous Coronary Intervention (PCI).

The invention is an effective solution to the problem known as the medical non-compliance problem. Reducing the non-compliance of patients offer them A better condition of their disease Better health Longer life expectancy Better quality of life The solution offers these great benefits at a limited cost. Solution can be applied to many diseases. More than 10% of the population can benefit from the invention. The invention keeps track of the patient's medicine usage. If the patient is not following the treatment that was prescribed to him it will send information over the telephone to the disease management system. The disease management system will then take the suitable action to help the patient back on track with his treatment. That action could for example be an automatic reminder call to the patient or in some cases a message to his physician to inform him of the situation.

The invention discloses a method by which the health care professional or patient may draw upon historical medical data concerning patients similarly situated in medical condition, to assist him / her in deciding on a clinical intervention procedure to select. This method is specifically tailored to the patient, as data is provided and evaluated from only similarly situated patients, and provides an expectation of potential outcome of the patient should one or the other of the options be selected. The invention further provides a database that may be used in order to provide this comparison based evaluation method. A computer based software system is further disclosed that implements the method. The invention more speiocifically provides a method by which a post-coronary event patient may make an informed decision of which post-coronary revascularization procedure to undergo in the future management of his disease. This method employs the patient's health status date (symptoms, function and quality of life), and provides projections of the patient's expected survival, risk, and 1-year health status outcome from the selection of revascularization procedure, such as Coronary Artery Bypass Grafting (CABG) or Percutaneous Coronary Intervention (PCI).

The concentrated feed for adult turbot consists of: alpha-starch 20-25 wt%, Peru red fish meal 30-40 wt%, soybean dregs 10-20 wt%, wheat flour 5-12 wt%, squid bowel powder 5-10 wt%, animal bone meal 5-10 wt%, beer yeast 3-7 wt%, and other seven kinds of material. The feed of the present invention has the features of: capacity of providing adult turbot under artificially raising with all the nutrients, good taste, high feed conversion rate, high stability in water, functions of promoting the growth of adult turbot and raising it disease resistance and survival rate, low cost, etc.

A feed additive for increasing the resistance of domestic animals and fowls to diseases and decreasing their cholesterol and blood fat is prepared from 14 Chinese-medicinal materials including fleece flower root, red sage root, haw, tangerine peel, etc through pre-treating, pulverizing and mixing.

The present invention discloses one kind of concentrated feed for rabbit. The concentrated feed consists of soybean dregs 2-6 wt%, rape seed dregs 7-13 wt%, feed yeast 8-14 wt%, DDGS8-12 wt%, light calcium carbonate 2-4 wt%, stone powder 5-7.5 wt%, rice hull powder 27-32 wt%, bentonite 5-7 wt%, trace elements 1-2 wt%, salt 0.5-1.5 wt%, choline 0.5-1.5 wt%, betaine 1-1.5 wt%, phytase 0.02-0.1 wt%, additive 0.5-1 wt%, vitamins 0.1-1 wt%, lysine 2-3 wt%, methionine 1-2 wt%, and Chinese medicinal stone 10-14 wt%. The concentrated feed can provide rabbit with sufficient energy, protein, vitamins and minerals to increase its growth speed and raise its disease resistance.

A computer multimedia type multifunctional biologic feedback apparatus for directing the feedback training and relax training of a trainee in order to treat its diseases and take care of its health features that it can automatically judge the variation of the trainee in physiological state during the training and prompt the trainee in multimedia mode (image, sound, etc).

The present invention refers to a medical diagnostic method based on proteomic and / or genomic patterns, using data obtained by mass spectrometry. The method also allows classifying the patients as to their disease stage Additionally, present invention also refers to two new biomarkers for the Hodgkin Disease medical diagnosis. Based on the SVM analysis, one localizes the windows of interest and later on uses the mass spectrum so to allow the biomarkers localization, so that the identification of said biomarkers occur by means of a 2D gel ou by mass spectrometry.

The invention herein is directed to a selective Aβ oligomer immunoassay capable of reliably and sensitively detecting Aβ oligomers in a biological sample of a patient. In one embodiment the inventive assay uses a pair of anti-AP oligomer antibodies, 19.3 and 82E1, to detect and quantify Aβ oligomers in a cerebrospinal fluid (CSF) sample. The inventive assay can be used to differentiate Alzheimer's disease (AD) patients from non-AD patients and / or to stratify AD patients according to the severity of their disease. The inventive assay can also be used as a target engagement assay that can measure bound Aβ oligomers as a surrogate end-point for the assessment of therapeutic efficacy and / or target engagement.

The invention relates to a method for determining a predictive function for discriminating patients according to their disease activity status, comprising steps of: a—measuring values of biological markers for each patient of a first group of patients having a first known disease activity status, and for each patient of a second group of patients having a second known disease activity status, the measured values forming a dataset b—analyzing the dataset for identifying biological markers which are differentially expressed between the first group of patients and the second group of patients, c—among the biological markers identified at step b, determining correlated markers as markers which are correlated with other markers above a predetermined significance level, d—removing from the dataset, values measured for a biological marker identified as correlated marker, e—analyzing the dataset obtained at step d for determining a predictive function that predicts a disease activity status of a patient as a combination of values of biological markers, f—evaluating an accuracy index associated with the predictive function determined at step e, g—repeating steps d to f by selectively removing from the dataset, values measured for one or several biological marker(s) identified as correlated marker(s), so as to gradually decrease the number of biological markers in the combination of value until the accuracy index reaches an expected level.

Systems and methods of individualized disease management are provided and use patient-specific, physician-defined rules to assist a patient in the management of their disease. The set of physician-defined rules for a patient can be maintained within the patient's blood glucose metering system and activated when a lifestyle event or blood glucose result is expected or recorded. Pattern analysis can be performed in real-time to provide physician-generated suggestions to a patient to positively influence their behavior toward managing their disease.

The efficient functional ecological fertilizer for date tree consists of biological organic fertilizer, urea, diammonium phosphate, potassium sulfate and Chinese medicinal stone powder in the weight ratio of 10 to 1.5 to 1.5 to 1.2 to 0.8. The fertilizer of the present invention can provides date tree with sufficient nutrients, raise its disease resistance, raise date fruit quality and raise its crack-resisting function.

A method of incentivising members of a disease management program to comply with the program by splitting the program into general program areas and specific program areas. The general program areas are relevant to all of the diseases with which members of the program are stricken while the specific program areas are only relevant to some disease managed by the program. Members of the program are awarded points for taking part in and achieving certain levels within all of the general program areas and within the specific program areas associated with the disease with which they are stricken. The points are accumulated and members are rewarded if their points reach a predetermined level. Furthermore, bonus points are awarded to the members for achieving certain levels in all of the program areas associated with their disease.

The invention discloses a composite microbial fertilizer for control of botrytis cinerea and a preparation method thereof. The composite microbial fertilizer is prepared by mixing of the following raw materials: a Str. Viridifaciens fermentation broth, a S. champavatii fermentation broth, an India bacillus fermentation broth, a B. mojavensis fermentation broth, and a Trichoderma ovalisporium fermentation broth. The strains involved in the invention can comprehensively utilize the antibiosis, competition, hyperparasitism and bacteriolysis effects between or within microbial species, or utilize secondary metabolites to induce the disease resistance of tomatoes, and can generate a variety of antibiotics like tetracycline, 7-aureomycin, champamycin A and B (antifungal antibiotics of heptaene) and champavatin to inhibit botrytis cinerea pathogenic bacteria and strengthen its disease prevention effect. The composite microbial fertilizer provided by the invention is safe to human and livestock, is environment-friendly, and does not produce drug resistance when applied to control of botrytis cinerea. The composite microbial fertilizer has the advantages of simple preparation method, low cost, and easy use.

This invention is a selective Aβ oligomer kit and immunoassay method capable of reliably and sensitively detecting Aβ oligomers in a biological sample of a patient. In one embodiment the inventive assay uses a pair of anti-Aβ oligomer antibodies, as capture and detection antibodies, to detect and quantify Aβ oligomers. The method can be used to differentiate Alzheimer's disease (AD) patients from non-AD patients and / or to stratify AD patients according to the severity of their disease.

A documentation system that allows adequate control of documentation in addition to an assessment of skills of the professionals involved includes plurality of software modules, each software module dedicated to a particular disease process or body system. Each software modules provides a checklist of assessment steps or an anatomical diagram of a particular body system or medical terminology. The medical data is accessed by inputting the abbreviations of a particular disease process or medical term displayed on an electronic device. It can then be downloaded to a PC and printed out in hard copy to be temporarily placed on the chart of the patient during an acute-episode, incident or accident or be permanently placed in the patient's chart to describe the patient's condition. In addition the pertinent medical data may be given to the patient to assist the patient in understanding his / her disease process, medical condition or medical terms.

The invention relates to medicine, in particular to acupuncture reflexotherapy. The inventive method consists in introducing a needle provided with a volume, plate or annular-shaped head into one of the predetermined, for example, auricular acupuncture points of a patient, wherein taking it through under the skin, the needle free end is withdrawn from the other predetermined point and a detachable retainer having plate or volume shape is secured thereon. The retainer can also be designed non-detachable and be formed by a bended free end of the needle rod. A required rate of lowering an excessive body weight is provided by exposure the zones of the indicated points to the head and / or retainer weight, or / and by changing a contact area thereof with the indicated points, and / or by a progradient correlation of intensity of the action on these points. In order to enhance the effect, pins and suspension members are used on the head and / or the retainer, as well as a contoured and / or wave-shaped surface of the needle rod. The proposed method and the needle design allow for a more efficient action on the selected acupuncture points, thereby significantly reducing the patient's excessive body weight or treating his or her diseases.

The invention discloses a dialogue management method of an AI-based triage system for the elderly, which relates to the medical technical field. The method comprises the following steps: acquiring user symptoms; acquiring and identifying the user symptoms by inquiring the user; obtaining and identifying the user symptoms by inquiring the user. The symptom degree obtaining step comprises: obtainingand identifying the severity of each symptom by inquiring the user; a reasoning condition generating step: generating reasoning statement according to user symptom and symptom severity; a user disease reasoning step: transmitting the reasoning statement to the reasoning module, and receiving the return value of the reasoning module; judging whether the diagnosis is confirmed or not: judging whether the diagnosis is confirmed or not according to the return value; if the diagnosis is not confirmed, inquiring again; if diagnosed, a natural language answer is generated from the diagnosed result.The invention solves the problem that the elderly can not accurately describe their disease condition, and mainly obtains more disease information of the elderly through dialogue and interaction.

Feed for adult trout is made from, by weight, 3-12 parts of pork powder, 18-26 parts of corn flour, 15-20 parts of rapeseed cake, 11-24 parts of longan shell powder, 22-33 parts of purple cabbage, 0.01-0.02 part of vitamin A, 0.5-1.5 parts of magnesium sulfate, 0.5-1.5 parts of Rhizoma Drynariae, 9.5-12 parts of Exocarpium Benincasae, 5.5-7.5 parts of diatom powder, and 5-10 parts of a modifying additive. The feed is suitable for adult trout, can promote further growth of trout, greatly enhance the activity and reproductivity of trout, promote immune cell differentiation in trout and enhance its disease resistance, never causes the rise of nitrogen, phosphorus and potassium content in water and has low impact on water quality.

The present invention describes clinically and medically important methods of monitoring the outcome of a cancer patient who is suffering from disease or who is undergoing treatment or therapy for his or her disease. More specifically, the invention provides a method of monitoring the progression of disease or cancer treatment effectiveness in a cancer patient by measuring the level of the extracellular domain (ECD) of the epidermal growth factor receptor (EGFR) in a sample taken from the cancer patient, preferably, before treatment, at the start of treatment, and at various time intervals during treatment, wherein a decrease in the level of the ECD of the EGFR in the cancer patient compared with the level of the ECD of the EGFR in normal control individuals serves as an indicator of cancer advancement or progression and / or a lack of treatment effectiveness for the patient. As another aspect of determining disease outcome and survival, the invention further provides assessing both EGFR and HER-2 / neu levels, in combination, in a patient sample. A finding of decreased levels of EGFR concomitantly with elevated or increased levels of HER-2 / neu relative to control levels indicates poor outcome and short time to progression.

Systems and methods for treating gastroesophageal reflux disease (GERD) includes minimally invasively implanting a stimulating device in a patient's esophagus in the region proximate the lower esophageal sphincter (LES). The patient is provided with a questionnaire related to his disease via an online service. The questionnaire is accessed on a mobile device, such as a cell phone, or on a computer with network access. The data from the sensors and the answers from the questionnaire are analyzed together by a health care provider using the online service. The data and answers are used to program the stimulating device, via the mobile device or computer, to optimize treatment.

Some examples of the disclosure are directed to the processing of medical claims data, electronic health records (EHR) data and other data to define disease / treatment pools and risk bands to assist in the treatment of diseases such as cancer. In some examples, in accordance with these defined disease / treatment pools and risk bands, participating practices (e.g., health care providers, clinics, cancer centers, etc.) can provide outpatient care in accordance with determined triage pathways that ensure patients receive the right care in the right place at the right time for symptoms related to their disease(s) and treatment, and determined clinical pathways that address, as applicable, appropriate imaging, pathologic testing and molecular diagnostics, delineating chemotherapy, radiation oncology, supportive care, and surgery. A centralized system may monitor electronic health records maintained by the participating practices to determine whether the participating practices are in compliance with determined clinical pathways.

The present invention describes clinically and medically important methods of examining, screening over time, and monitoring the outcome of a cancer patient who is undergoing treatment or therapy for his or her disease. More specifically, the invention provides a method of monitoring the progression of disease, or the effectiveness of cancer treatment, in a cancer patient by measuring the levels of one or more analytes of the plasminogen activator (uPA) system, namely, uPA, PAI-1 and the complex of uPA:PAI-1, in a sample taken from the cancer patient, preferably, before treatment, at the start of treatment, and at various time intervals during treatment. As a result of performing the method, an increase or elevation in the levels of one or more of the PA system analytes in the cancer patient compared with the levels one or more of the respective PA system analytes in normal control individuals serves as an indicator of cancer advancement or progression and / or a lack of treatment effectiveness for the patient.